

Nigericin (sodium salt)

Catalog No: tcsc5717

Available Sizes

| Size: 5mg | |
|------------------------------|--|
| Size: 10mg | |
| Size: 25mg | |
| Size: 50mg | |
| Size: 100mg | |
| Specifications | |
| CAS No: 28643-80-3 | |

Formula:

 $C_{40}H_{67}NaO_{11}$

Pathway: Membrane Transporter/Ion Channel

Target: Potassium Channel

Purity / Grade:

>98%

Solubility:

Ethanol : \geq 50 mg/mL (66.94 mM); DMSO : 5 mg/mL (6.69 mM; Need ultrasonic and warming)

Alternative Names:

Sodium Nigericin

Copyright 2021 Taiclone Biotech Corp.



Observed Molecular Weight:

746.94

Product Description

Nigericin sodium salt is an antibiotic from *Streptomyces hygroscopicus* that works by acting as an H⁺, K⁺, and Pb²⁺ ionophore.

In Vitro: Nigericin (0.1 μ M) decreases inhibits proliferation and clonogenicity of H460 lung cancer cells in a dose dependent manner. Nigericin inhibits migration and invasion of H460 lung cancer cells^[1]. Nigericin (0.1-10 nM) has apparently a dual effect on cell volume, that is a shrinking effect at lower Nigericin concentrations and a swelling effect at higher concentrations. Nigericin (0.1-1 nM) significantly decreases cytosolic pH (pHi), and slightly increases the pHi at 5 and 10 nM^[2]. Nigericin exhibits higher toxicity on S18 cells than S26 cells, with IC₅₀ of 2.03±0.55 μ M and 4.77±2.35 μ M, respectively. Nigericin can selectively kill cancer stem cells in NPC in vitro. Nigericin dramatically reduces the migration ability of S18 and HONE-1 cells^[3]. Nigericin exhibits gteat toxicity for the HT29 and SW116 cell line with IC₅₀ of 12.92±0.25 μ mol and 15.86±0.18 μ mol. Nigericin also shows a decreased ability to form colonies under anchorage-independent conditions in a standard soft agar assay^[4].

In Vivo: Ngericin (4 mg/kg, i.p.) significantly reduces tumor growth and acts synergistically with the chemotherapeutic agent DDP, as shown by the tumor volumes. Nigericin markedly decreases Bmi-1 in vivo. Overexpression of Bmi-1 partially restores CSC content and metastatic ability of NPC cells under Nigericin treatment. The downregulation of Bmi-1 may be involved in the inhibitory effect of Nigericin on CSCs in NPC^[3].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!

Copyright 2021 Taiclone Biotech Corp.